RMC-6236 + Gemcitabine + nab-paclitaxel + Irinotecan + Liposomal irinotecan + 5-fluorouracil + leucovorin + Oxaliplatin
Phase 3Active 2 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Cancer
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Trial Timeline
Oct 16, 2024 → Dec 1, 2027
NCT ID
NCT06625320About RMC-6236 + Gemcitabine + nab-paclitaxel + Irinotecan + Liposomal irinotecan + 5-fluorouracil + leucovorin + Oxaliplatin
RMC-6236 + Gemcitabine + nab-paclitaxel + Irinotecan + Liposomal irinotecan + 5-fluorouracil + leucovorin + Oxaliplatin is a phase 3 stage product being developed by REVOLUTION Medicines for Pancreatic Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06625320. Target conditions include Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Cancer were approved
Approved (9) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06625320 | Phase 3 | Active |
Competing Products
20 competing products in Pancreatic Cancer